Search clinical trials for: peginterferon alfa-2a [Pegasys]

Total 825 results

Xiamen Amoytop Biotech Co., Ltd.
Peking University People's Hospital

Completed

Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C (PEGIFN)

Chronic Hepatitis C

China
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Chronic Hepatitis B

China
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Chronic Hepatitis B

China
Biocad

Completed

An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

Hepatitis | Hepatitis C

Belarus, Russian Federation, India, Thailand
Hoffmann-La Roche

Completed

A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy

Hepatitis C, Chronic

Germany
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.

Hepatitis C, Chronic

Russian Federation
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Hepatitis B, Chronic

Russian Federation
Hoffmann-La Roche

Completed

A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies

Hepatitis B, Chronic

Taiwan, United States, New Zealand, Singapore
The Catholic University of Korea
Ulsan University Hospital; Yonsei University; Kyungpook National University Hospital and other collaborators

Completed

100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)

Sustained Virologic Response | IL28B Polymorphism

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).

Hepatitis B, Chronic

China, Hong Kong, Australia, Germany, Taiwan, Singapore, France, United States, Korea, Republic of, New Zealand, Thailand, Russian Federation, Brazil
Hoffmann-La Roche

Terminated

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.

Hepatitis B, Chronic

Turkey
Hoffmann-La Roche

Completed

A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response

Hepatitis C, Chronic

Israel
Hoffmann-La Roche

Completed

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

Hepatitis C, Chronic

United States
Hoffmann-La Roche

Completed

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Hepatitis B, Chronic

China, Hong Kong, Taiwan, Singapore, Korea, Republic of, New Zealand, Thailand, Brazil, Russian Federation, Australia
Hoffmann-La Roche

Completed

PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Hepatitis C, Chronic

United States, Puerto Rico
Hoffmann-La Roche

Completed

Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253

Hepatitis B, Chronic

Italy
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

Hepatitis B

China
Seng Gee Lim
Roche Pharma AG

Unknown

Peg-interferon for Inactive Chronic Hepatitis B Carriers (INACTIVE)

Chronic Hepatitis, B Virus | Carrier of Viral Hepatitis Type B

Singapore
Hoffmann-La Roche

Completed

An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B

Hepatitis B, Chronic

Morocco
Hoffmann-La Roche

Completed

PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)

Hepatitis C, Chronic

France, Sweden, Austria, Hungary, Poland, Romania, Slovenia, Croatia, Serbia, Canada, Brazil, Morocco, Mexico, Macedonia, The Former Yugoslav Republic of
Third Affiliated Hospital, Sun Yat-Sen University

Completed

Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA

Antiviral Treatment of Chronic Hepatitis B
National Institute of Diabetes and Digestive and...
University of Pittsburgh; National Center for Research Resources (NCRR)

Terminated

Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B (HBRN)

Hepatitis B

United States, Canada
Hoffmann-La Roche

Completed

PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Hepatitis C, Chronic

Belgium, Ireland, Italy, United Kingdom
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.

Hepatitis B, Chronic

Korea, Republic of
The Immunobiological Technology Institute (Bio-Manguinhos)...

Completed

Comparative Pharmacokinetics and Pharmacodynamics of Peginterferon BIP48 and 40kDa in Healthy Volunteers

Chronic Viral Hepatitis C

Brazil
Hoffmann-La Roche

Terminated

Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)

HIV/HCV Coinfection

Belgium
National Institute of Diabetes and Digestive and...

Completed

Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection

Hepatitis B

United States, Canada
Hoffmann-La Roche

Completed

SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).

Hepatitis B, Chronic

Bulgaria
National Taiwan University Hospital
National Science Council, Taiwan

Unknown

Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B

Hepatitis B, Chronic

Taiwan
The Second Affiliated Hospital of Chongqing Medical...
The First Affiliated Hospital of Nanchang University; First Affiliated Hospital... and other collaborators

Unknown

Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides

Hepatitis B
Hoffmann-La Roche

Completed

A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B

Hepatitis B, Chronic

China
Ministry of Health, Malaysia

Unknown

Malaysia Stop Tyrosine Kinase Inhibitor Trial (MSIT)

Leukemia, Chronic Myeloid

Malaysia
M.D. Anderson Cancer Center

Terminated

Pegasys in Patients With Chronic Myeloid Leukemia (CML)

Leukemia

United States
Novira Therapeutics, Inc.

Completed

Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients

Chronic Hepatitis B

New Zealand
Novira Therapeutics, Inc.

Completed

Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients

Chronic Hepatitis B

United States, Taiwan, Singapore, Korea, Republic of, China
Hospital Clinico Universitario San Cecilio

Completed

Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4

HIV Infections | Hepatitis C

Spain
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

Hepatitis C, Chronic

United States
Huashan Hospital

Completed

Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy

Chronic Hepatitis B

China
Xiamen Amoytop Biotech Co., Ltd.

Completed

Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients

Chronic Hepatitis C

China
Ruijin Hospital

Unknown

An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients

Chronic Hepatitis B
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

Hepatitis B, Chronic

Belgium, United States, Israel, China, Australia, Germany, Russian Federation, Ukraine, United Kingdom, Poland, Bulgaria, Italy
Hoffmann-La Roche

Completed

A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Russian Federation
Hoffmann-La Roche

Completed

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Hepatitis C, Chronic

Belgium, United States, Germany, Canada, Austria, Switzerland, Puerto Rico, Australia, Brazil, Mexico
Hoffmann-La Roche

Completed

A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Hepatitis C, Chronic

Israel
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.

Hepatitis C, Chronic

Mexico
Hoffmann-La Roche

Completed

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

Hepatitis C, Chronic

United States
Hoffmann-La Roche

Completed

An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study

Hepatitis B, Chronic

Serbia
China Medical University Hospital

Completed

Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B

Hepatitis B, Chronic

Taiwan
Bristol-Myers Squibb

Completed

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir (PEDESTAL)

Hepatitis C Virus

Belgium, Germany, Spain, United States, Canada, Brazil, Austria, France, Israel, Switzerland, Italy, Russian Federation, Czechia, Poland, United Kingdom
Hoffmann-La Roche

Completed

POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).

Hepatitis C, Chronic

Brazil

3

Subscribe